Experts Weigh In On Early Clinical Experience With Nerivio Migra in Acute Migraine
November 28th 2019With Theranica’s Nerivio Migra acute migraine device named a top invention of the year, three experts in migraine shared their insight into its clinical application in the early days of its availability, with varying experiences.
Exploring the Role of B Cells and CD20 in Multiple Sclerosis
November 28th 2019Although there are no cures for MS at present, the treatment landscape has changed significantly, with over a dozen approved disease-modifying therapies (DMTs) representing multiple classes of agents with different mechanisms of action.
Midazolam Nasal Spray Available Soon for Seizure Clusters
November 27th 2019Midazolam nasal spray CIV, marketed under the brand name Nayzilam, is expected to become available in retail pharmacies early next month after its approval for the treatment of intermittent, stereotypic episodes of frequent seizure activity in epilepsy.
Andre Machado, MD, PhD: Referrals for Deep Brain Stimulation
November 26th 2019The Chairman of the Neurological Institute at Cleveland Clinic discussed getting patient referrals for deep brain stimulation and how often patients miss the window during which the treatment could offer them benefit.
Combination of CSF Neurofilament and TDP-43 Improves ALS Diagnostic Performance
November 26th 2019The use of cerebrospinal neurofilament light chain and TAR DNA‐binding protein 43 in tandem may offer stronger biomarkers for amyotrophic lateral sclerosis diagnosis, with NfL also offering a measure of disease progression.
Otaplimastat Is Safe and Feasible in Stroke Alongside tPA
November 21st 2019Findings of a phase 2 assessment has suggested that otaplimastat can be safely administered in patients with stroke who are being treated with recombinant tissue plasminogen activator and is realistic to be further studied.
Topiramate Liquid Formulation IND Gets Regulatory Go-Ahead
November 21st 2019The investigational new drug application for OWP Pharmaceuticals’ first-ever liquid formulation of topiramate, intended to offer a new delivery alternative for the therapy in epilepsy and migraine treatment, has been approved.
Ubrogepant Provides Significant Relief From Migraine Pain, Bothersome Symptoms
November 19th 2019An analysis of ACHIEVE II suggests that the oral CGRP antagonist from Allergan provides significant pain freedom and relief of the most bothersome symptoms for adults with migraine for at least one dose assessed.